CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
CytomX reported Q2 revenue of $1.4 million, down from $18.7 million in the prior year due to the conclusion of collaborations with Bristol Myers Squibb and Astellas, while operating expenses increased to $25.2 million. Despite the revenue decline, the company strengthened its balance sheet with $330.3 million in cash and equivalents, providing a runway into the second half of 2028, supplemented by a $37.0 million payment received from Regeneron in July.
Key figures
- Revenue
- $1.4 million
- Guidance
- Cash runway expected to extend to at least the second half of 2028
- Net loss
- $20.7 million
- Cash position
- $330.3 million
- Regeneron payment
- $37.0 million
- Operating expenses
- $25.2 million
- Varseta m phase1 patients
- 113
- Potential regeneron milestones
- $4.0 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.